Tags : Christian Schneiter

Banking & Finance

Vischer advises Norgine Ventures in the financing of Lunaphore

Norgine Ventures has provided financing of approx. EUR 10 million to Lunaphore Technologies, a privately owned Swiss company spun out from EPFL. The financing was realised in form of private bonds with warrants which can be drawn down in multiple tranches. Based in Lausanne, Lunaphore Technologies has developed a game-changing chip technology which can extract […]

Capital Markets

Advestra advised Keda Industrial Group and Ningbo Shanshan on their

As we have informed last 28th July, Keda Indus­tri­al Group and Ningbo Shan­shan were among the first com­pan­ies which suc­cess­fully lis­ted glob­al depos­it­ary receipts (GDRs) on SIX Swiss Exchange. Keda Indus­tri­al Group, whose A shares are lis­ted on the Shang­hai Stock Exchange, raised gross pro­ceeds in the amount of approx. USD 173 mio. from the offer­ing of GDRs and Ningbo Shan­shan, […]


Vischer: Relief Therapeutics launches Level 1 ADR Program in the

Relief Therapeutics, a biopharmaceutical company, has launched a Level 1 American Depositary Receipt (“ADR”) program in the United States. From 18 November 2021, ADRs can be traded over-the-counter. Relief’s ADR program complements the existing main listing of the shares on the SIX Swiss Exchange. J.P. Morgan has been appointed as the depositary bank for the […]

Capital Markets

Vischer advised Relief Theraputics on private placement of CHF15 m

Biopharmaceutical company Relief Theraputics Holding, has a binding agreement with two institutional U.S. investors completed. The contract provides for the purchase of Relief shares with a total value of CHF 15 million, which come from Relief’s own shares, which were issued from the authorized share capital, excluding the subscription rights of existing shareholders. The transaction […]

Deal & transactions

Vischer in the acquisition of Evitria Group by Atlas Antibodies

Atlas Antibodies, a global developer of advanced reagents for biomedical research based in Sweden, has agreed to acquire Evitria Group from its shareholders. The transaction closed on August 5, 2021.   Vischer advised the sellers on this transaction. The team, headed by partner Jürg Luginbühl (corporate/ m&a, pictured) partner Marc Ph. Prinz (labor law), partner […]

Capital Markets

Vischer with Relief Therapeutics on the issuance of 1 billion

  Relief Therapeutics Holding, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has issued 1,000,000,000 additional registered shares out of the authorised share capital approved by the Annual General Meeting on 18 June 2021.   The new shares were fully subscribed at par value by the Relief’s wholly […]

Capital Markets

Relief Therapeutics private placement of CHF 15 million. The advisors

  H.C. Wainwright acted as sole placement agent in connection to the private placement of 71,428,572 shares in Relief Therapeutics Holding, a Swiss biopharmaceutical company listed at SIX Swiss Exchange, at a price of CHF 0.21 per share.    The aggregate gross proceeds from the private placement are expected to be approximately CHF 15 million, before deducting the placement […]